Terkko Navigator / European Urology

Re: Partial Nephrectomy Versus Radical Nephrectomy for cT2 or Greater Renal Tumors: A Systematic Review and Meta-analysis

Clinical Acumen Versus Androgen Receptor Variant 7 Circulating Tumor Cells in Decision-Making for Men with Advanced Prostate Cancer

Climbing over the Barriers of Current Imaging Technology in Urology

Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcin

Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27–30: Salvage Robotic Radical Prostatectom

Re: Long-term Outcomes for Men in a Prostate Screening Trial with an Initial Benign Prostate Biopsy: A Population-based Cohort

Reply to Liang Sun and Yi Feng’s Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for St

Re: Jack R. Andrews, Thomas Atwell, Grant Schmit, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2019;76:244–51

Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive

Re: Giorgio Gandaglia G, Peter Albers, Per-Anders Abrahamsson, et al. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. Eur Urol 2019;76:142–50

Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study

Response of Primary Renal Cell Carcinoma to Systemic Therapy

Re: Manfred Wirth, Nicola Fossati, Peter Albers, et al. The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. Eur Urol 2019;76:179–86

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study

Reply to Won Ho Kim, Hyun-Kyu Yoon, Chang Wook Jeong’s Letter to Editor re: Carlo Bravi, Emily Vertosick, Nicole Benfante, et al. Impact of Acute Kidney Injury, Its Duration on Long-term Renal Function After Partial Nephrectomy. Eur Urol. In press. h

The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)

Re: Carlo Bravi, Emily Vertosick, Nicole Benfante, et al. Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.040

Effect of Renal Mass Biopsy on Subsequent Nephrectomy Outcomes: A Population-based Assessment

Hypospadias increased prevalence in Surveillance Systems for Birth Defects is observed: Next to climate change are we going towards a human fertility alteration?

Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer

Congress Calendar

Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2019; 75,5: 853-860

Reply to Bernhard Liedl, Klaus Goeschen, and Florian Wagenlehner’s Letter to the Editor re: Benoit Peyronnet, Emma Mironska, Christopher Chapple, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. E

Re: Benoit Peyronnet, Emma Mironska, Christopher Chapple, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol 2019;75:988–1000: Overactive Bladder Symptoms Can Be Caused by Pelvic Organ Prol

Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol

Re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548–51

Reply to Zeynep G. Gul, Alberto Martini, and Carl A. Olsson's Letter to the Editor re: Jacob A. Burns, Adam B. Weiner, William J. Catalona, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846–52

Translating Science to Medicine: When Will the Rubber Meet the Road?

Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study

Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend’s Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Ca

Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates

Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel

Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset

Congress Calendar

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities

Reply to Jochen Walz. Let's Keep It at One Step at a Time: Why Biparametric Magnetic Resonance Imaging Is Not the Priority Today. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.028: How to Implement High-quality, High-volume Prostate Ma

Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti’s Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prosta

Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review And Meta-analysis. Eur Urol. In press. https://doi.org/10.

The Prevalence of Y-chromosome Microdeletions in Oligozoospermic Men: A Systematic Review and Meta-analysis of European and North American Studies

Perspectives on a Global Change in Testicular Cancer Incidence

The Finnish Randomized Trial of Adjuvant Radiotherapy Versus Observation After Prostatectomy: Almost a Trial of Adjuvant Versus Late Salvage Radiotherapy

Impact of Three-dimensional Printing in Urology: State of the Art and Future Perspectives. A Systematic Review by ESUT-YAUWP Group

Evolution of Robot-assisted Partial Nephrectomy: Techniques and Outcomes from the Transatlantic Robotic Nephron-sparing Surgery Study Group

Limited Upstaging in Luminal Subtype Tumors: Ready for Clinical Practice?

Congress Calendar

Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry